See this page online at: http://www.bioscienceworld.ca/tomarket
Sign up for your subscription and keep up-to-date.
Stay updated on the latest news and technologies with Bioscienceworld's newsletters.
Five to choose from.
|
April 07 2011
Anti-cancer screening technology from U of T to be commercialized The Ontario Institute for Cancer Research (OICR) says it is providing $500,000 in funding over two years for the commercialization of a new high-throughput screening technology directed at the discovery of anticancer drugs.
|
|
January 24 2011
Celgene must give Canada drug data, court rules U.S. biotechnology firm Celgene Corp. must provide information to Canadian regulators who want to review the price it charges for its Thalomid drug, Canada's Supreme Court ruled on January 20, 2011.
|
|
January 24 2011
An innovative financing tool at your fingertips The Canadian biotech landscape has been hit hard by one of the most severe market downturns in recent decades. Those that have survived have needed to turn to non-traditional mechanisms to raise additional funds and to be on the lookout for new methods to complement their financing strategies.
|
|
November 24 2010
CSPC meets to evolve science policy Playing on the success of an inaugural conference in 2009, the Canadian Science Policy Conference (CSPC) drew 400 participants from academia, government and industry to Montreal this month in one of several efforts to stimulate national dialogue on the formation of science policy in this country. The 2010 Conference motto, “Building Bridges for the Future of Science Policy,” trains a keen lens on the short and long term aims of the meeting: in the absence of established canon or top down pains to create it, conference organizers were looking to provide an environment to encourage the grassroots development of a network that will include all stakeholders in the creation of Canadian science policy.
|
|
October 26 2010
Innovation takes leadership Building off the tremendous success of last year’s inaugural conference, the Innovation Takes Leadership: Ivey Global Health Innovation Conference remains focused on the intersection of innovation and leadership, both being required to face the daunting challenges of Canada’s health care system.
|
|
September 14 2010
International Thyroid cancer survey results places Canada at the bottom According to a recent international survey conducted by the Thyroid Cancer Alliance (TCA), Canadian Thyroid cancer patients have the longest wait for surgery amongst all the countries surveyed.
|
|
August 27 2010
More dialogue needed about the costs of cancer drug treatments Canadian and US physicians have similar views on cancer drug costs and cost effectiveness, reveals the first comprehensive survey of medical oncologists' attitudes, led by Sunnybrook researchers and published in the Journal of Clinical Oncology.
|
|
July 29 2010
Federal government invests in innovative small and medium-sized firms The federal government announces investments of $273,000 to Boreal Genomics Inc. and $476,000 to Day4 Energy Inc. from the National Research Council of Canada's Industrial Research Assistance Program (NRC-IRAP).
|
|
July 15 2010
First nasal vaccine approved in Canada to prevent seasonal influenza AstraZeneca Canada Inc. announces that Health Canada has approved FluMist® (Influenza Vaccine, Live, Attenuated) for the prevention of seasonal influenza. FluMist is the first vaccine in Canada that is administered as a gentle mist sprayed into the nose.
|
|
April 30 2010
OICR invests in personalized medicine spin-offs The Ontario Institute for Cancer Research s has made equity investments in two new University of Toronto spin-off projects that are focused on developing molecular diagnostic technologies for use in cancer screening and treatment.
|
|
April 20 2010
Health Canada approves Afinitor Novartis Pharmaceuticals Canada Inc. announced that Afinitor® (everolimus), a once-daily oral cancer treatment, has been approved by Health Canada for patients with metastatic renal cell carcinoma (mRCC), also known as advanced kidney cancer, after failure of initial treatment with VEGF-receptor targeted therapies Sutent® (sunitinib) or Nexavar® (sorafenib).
|
|
April 20 2010
Tentative new date for the FDA Advisory Committee to review Tesamorelin drug application Theratechnologies announces that the U.S. Food and Drug Administration (FDA) has set a tentative new date of May 27, 2010 for the Endocrinologic and Metabolic Drugs Advisory Committee meeting to review Theratechnologies’ new drug application for tesamorelin.
|
|
February 16 2010
New vaccine for Pneumococcal disease receives Health Canada approval Following a Priority Review, Health Canada has approved Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)) for children aged six weeks through five years for active immunization against invasive pneumococcal disease.
|
|
February 16 2010
FDA gives fast track designation to Æterna Zentaris’ anti-cancer compound The U.S. Food and Drug Administration (FDA) have granted Fast Track designation for Æterna Zentaris Inc. PI3K/Akt pathway inhibitor compound, perifosine (KRX-0401), for the treatment of relapsed/refractory multiple myeloma.
|
|
January 26 2010
Forbes Medi-Tech launches Del Monte Heart Smart Pineapple Forbes Medi-Tech Inc. announces the launch of a new pineapple juice containing the company’s proprietary cholesterol-lowering ingredient, Reducol™ in the Philippines.
|
|
December 03 2009
Health Canada approves GlucaGen® for treatment of severe hypoglycemia in diabetes patients Paladin Labs Inc. announces that the Biologics and Genetic Therapies Directorate of Health Canada has approved GlucaGen® (recombinant glucagon for injection) for the treatment of severe hypoglycemia in diabetic patients being treated with insulin.
|
|
December 03 2009
New type 2 diabetes tablet offers blood glucose control without weight gain Merck Frosst Canada Ltd. new diabetes treatment, JANUMET™ (sitagliptin/metformin HCI, MSD), has received Notice of Compliance (NoC) in Canada.
|
|
November 06 2009
FDA approves Pennsaid® topical solution Covidien, a leading global provider of healthcare products, and Nuvo Research Inc., a Canadian drug development company, announce that the U.S. Food and Drug Administration (FDA) has approved the new drug application for Pennsaid® topical solution.
|
|
September 25 2009
YM Biosciences reports nimotuzumab approved for marketing in Mexico YM BioSciences Inc., reports that nimotuzumab has been approved for marketing in Mexico. YM BioSciences also announces that it has enrolled the first two patients in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from non-small-cell lung cancer (NSCLC).
|
|
September 10 2009
Korean court rules against Canadian company Immunotec Inc. will be filing an appeal to a decision made by the Korean Courts to stop the distribution of Immunocal products because they don’t have the exclusive rights to distribute them.
|
|
September 09 2009
Canadian Biotech: Investing for the Long Run By David Sable
While I did see some long faces back in April at Toronto’s BioFinance 2009, as speakers and panelists repeated predictions of doom for Canada’s biotechnology industry, I did not see any bodies in ditches or vultures circling. |
|
September 08 2009
Survey says: Help is needed for Canada's Biotech industry, and fast By Shawn Lawrence
We asked and you responded with the Hot Button Issues facing Canadian biotech |
|
September 08 2009
The first national Canadian science policy conference Compiled by Shawn Lawrence
Science policy is the discipline that lies at the interface of scientific enterprise and public administration. |
|
September 03 2009
UCB's Cimzia™ approved by Health Canada for adult patients suffering from moderate to severe rheumatoid arthritis Health Canada has approved UCB Canada Inc. Cimzia™, PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis and is now available in Canada.
|
|
July 14 2009
Coming FDA decision renews interest in Nuvo Research Nuvo Research could see extensive gains leading up to an FDA decision expected to come down on August 5, 2009 as investors gain confidence in the company once again.
|
|
April 16 2009
Urodynamix announces completion of commercial shipment Urodynamix Technologies Ltd. has completed its first commercial shipment of uroNIRS 2000 product to Medical Measurement Systems B.V., a leading developer and distributor of medical diagnostic systems for urology, gastroenterology and neurology headquartered in the Netherlands.
|
|
March 16 2009
Letters to the Editor Xylon approves of any support the feds or the provinces can give in these difficult times.
|
|
January 30 2009
Health Canada approves ZELDOX® Pfizer Canada Inc. announces that Health Canada has approved ZELDOX (ziprasidone hydrochloride), for use in the treatment of acute manic or mixed episodes associated with bipolar disorder.
|
|
January 26 2009
Amorfix awarded “Life Science Company of the Year” by The Biotechnology Initiative Amorfix Life Sciences Ltd. has been selected as the inaugural recipient of the “Life Science Company of the Year” by The Biotechnology Initiative.
|
|
October 27 2008
Miraculins executes license agreement with Mount Sinai Hospital Miraculins Inc. executes a license agreement with Mount Sinai Hospital to acquire the rights to commercialize a portfolio of biomarkers for use in developing diagnostic assays for the early detection of preeclampsia, a disease of growing incidence and the leading cause of maternal and prenatal deaths worldwide.
|
|
October 10 2008
CellaVision receives the first Canadian orders for the new body fluid application CellaVision AB (publ), which develops and sells digital morphology products for the routine analysis of blood and other body fluids, receives its first orders for the recently launched product, CellaVision® Body Fluid Application from Canada.
|
|
September 25 2008
Outgoing Alberta Medical Association president calls for ‘patient-focused’ health care system Predicting that the new single health board, Alberta Health Services, will be "the catalyst" for many changes in Alberta's health system, outgoing Alberta Medical Association (AMA) president Dr. Darryl D. LaBuick called for “a patient-focused system”.
|
|
September 19 2008
Nova Scotia Business Inc. - Nova Scotia biotechnology company reaches new markets Made in Nova Scotia health products will soon be stocked on more drugstore shelves south of the border.
|
|
July 24 2008
U of S $50,000 BioVenture Challenge Business Plan competition launched The University of Saskatchewan (U of S) Industry Liaison Office (ILO) and Saskatchewan Agriculture are partnering to sponsoring the 2008 BioVenture
Business Plan Challenge to assist youth with launching their bio-based business ideas. |
|
July 18 2008
Call for nominations – OCRI Life Sciences Achievement Awards A celebration of excellence in the Ottawa and Eastern Ontario life sciences community The OCRI Life Sciences Achievement Awards are designed to recognize outstanding individual or group achievements in the Ottawa and Eastern Ontario life sciences sector.
|
|
July 18 2008
Dalton Pharma Services expands its contract analytical services Dalton Pharma Services announces the expansion of its contract analytical services with the commissioning of two validated LC-MS/MS instruments, which have been qualified for GMP testing of pharmaceutical products.
|
|
June 27 2008
Canada's bio-economy growing but at risk, study finds Canada's biotechnology sector is strong and growing, but immediate skills shortages threaten its sustainability as an important emerging platform of Canada's economy.
|
|
June 23 2008
Canada's bioactive paper research leaders gather in Finland to accelerate development Researchers working to develop inexpensive paper that can destroy, deactivate and detect deadly pathogens, such as salmonella and SARS, will share their expertise with the world as the first ever international conference on bioactive paper kicks off in Espoo, Finland.
|
|
June 09 2008
Miraculins to internally develop clinical grade immunoassays Miraculins Inc. adds a Luminex Bio-Plex 200 Protein Array System to its laboratory, which will enhance the company's capabilities to develop clinical grade immunoassays internally.
|
|
May 27 2008
Paladin Labs Inc. Plan B® now available over the counter in Canada Paladin Labs Inc. announces that the National Association of Pharmacy Regulatory Authorities (NAPRA) has granted Plan B(R) full Over-the-Counter status (OTC) (schedule III). Previously, Plan B(R) had behind the counter status (schedule II).
|
|
May 23 2008
DiagnoCure reports key milestones in commercialization DiagnoCure Inc. reports key milestones related to the market introduction of its PrevistageTM GCC colorectal cancer staging test, and the expanded utility of its PCA3 marker for the detection of prostate cancer.
|
|
May 12 2008
Angiotech expands Quill™ SRS product offering Angiotech Pharmaceuticals, Inc. receives 510(k) clearance from the U.S. Food and Drug Administration (FDA) to begin marketing sizes 3-0 and 4-0 of its Quill Self-Retaining System (SRS) Polydioxanone (PDO) product line.
|
|
March 14 2008
CardioComm Solutions sells multiple systems to Canadian Heart Research Centre CardioComm Solutions Inc. announces that it has sold and delivered 10 WebEKG systems to the Canadian Heart Research Centre.
|
|
March 13 2008
Cultivating Canada's Science and Technology Government leadership and investment in science and technology has played a significant role in stimulating innovation, knowledge and wealth creation across Canada. As the federal government begins to implement the strategic directions of Mobilizing Science and Technology to Canada’s Advantage, released in May 2007, Pierre Coulombe, president of the National Research Council of Canada (NRC), spoke with Biotechnology Focus about the plan and the council.
|
|
February 15 2008
OGI officially launches the Genomics Sector Innovation Network (G-SIN) portal The Ontario Genomics Institute (OGI), in partnership with the Ontario Ministry of Research and Innovation (MRI) launches the Genomics Sector Innovation Network (G-SIN).
|
|
December 18 2007
Vasogen and Grupo Ferrer announce initial roll-out of Celacade Vasogen Inc. and Grupo Ferrer Internacional, S.A. announce the receipt of initial orders for Vasogen's Celacade(TM) System in Germany.
|
|
November 15 2007
BIOTECanada welcomes new investment commitment for innovative technologies The national biotechnology industry association lauded the efforts of the Government of Ontario and leading investment institutions on the creation of the new Ontario Venture Capital Fund.
|
|
November 15 2007
BioNorth conference focuses on driving innovation and commercialization through partnerships in biotechnology For the 14th consecutive year, the BioNorth Biotechnology and Life Sciences Conference will highlight the work and achievements of Canada’s life sciences companies.
|
|
November 02 2007
Zecotek announces first commercial production run of solid-state photo detectors Zecotek Medical Systems Inc. announces that the Malaysian Institute for Micro-electronics Systems (MIMOS), has successfully completed the first commercial production run of the company's new-generation Micro-pixel Avalanche Photo Diodes (MAPD) solid-state photo detectors.
|
|
August 24 2007
Genesis Genomics Inc. secures $ 2.6 million in financing Genesis Genomics Inc. (GGI) announces the closing of the second round of its private placement financing.
|
|
August 24 2007
Urodynamix announces grant of stock options Urodynamix Technologies Ltd., a company developing a portfolio of non-invasive diagnostic products for a variety of large and growing global markets, reports that it has issued 600,000 incentive stock options to four directors of the company.
|
|
August 10 2007
UBC researcher suggests NZ as fix for soaring Canada Rx drug prices A UBC researcher is suggesting Canadians look at New Zealand as an answer to its soaring Rx drug prices. Leveraging the purchasing power of a New Zealand-style universal pharmacare plan could save Canadians billions of dollars a year, according to a detailed cost comparison from the Centre for Health Services and Policy Research (CHSPR) at the University of British Columbia.
|
|
August 10 2007
Agrium's earnings exceed previous record by 60% Agrium Inc. announces its highest ever quarterly earnings, with net earnings for the second quarter of 2007 of $229-million ($1.70 diluted earnings per share), a more than 60% increase over net earnings of $142-million ($1.06 diluted earnings per share) for the same period in 2006.
|
|
July 13 2007
BIOTECanada product launch stewardship policy for agricultural biotechnology BIOTECanada announces the adoption of a new Product Launch Stewardship Policy for agricultural biotechnology, encouraging its members to facilitate the flow of goods in commerce and minimize the potential for trade disruptions with respect to products of agricultural biotechnology.
|
|
July 13 2007
ARIUS announces second quarter fiscal 2007 financial results ARIUS Research Inc. releases its financial and operational results for the second quarter, ended May 31, 2007.
|
|
July 03 2007
Amorfix announces 2007 year end results Amorfix Life Sciences announces its operational and financial results for the year ended March 31, 2007, as well as financial results for the fourth quarter.
|
|
June 18 2007
Amorfix receives ISO13485 certification Amorfix Life Sciences has achieved ISO13485:2003 certification for its in vitro diagnostic EP-vCJD TM test for detection of aggregated misfolded proteins in variant Creutzfeldt-Jacob Disease (vCJD).
|
|
June 08 2007
Amendments made to Intellectual Property Regulations benefit universities and businesses The Canadian Intellectual Property Office (CIPO) announces the coming into force of regulatory amendments, effective immediately, ensuring Canada's intellectual property (IP) regime is more user-friendly, cost-effective and responsive to the needs of Canadian universities and businesses.
|
|
June 04 2007
Protox reports 2006 financial results and achievements Protox reports it has completed 2006 with cash resources of $9,977,259 and a working capital of $8,918,615. Subsequently, the company also raised an additional $583,000 from the exercise of outstanding share purchase warrants.
|
|
May 22 2007
Allon Therapeutics releases first quarter operating results Allon Therapeutics Inc. releases its first quarter operating results, announcing that the company remains on track to achieve all of its 2007 milestones, including initiating a third Phase II human clinical trial.
|
|
May 22 2007
Med BioGene Inc. reports financial results for 2006 Med BioGene Inc. (MBI) reports its financial results for 2006, with recent scientific and business highlights.
|
|
May 17 2007
U of S researcher awarded $242,000 for potential new anti-inflammatory drug University of Saskatchewan health researcher John Gordon has been awarded $242,000 from the Canadian Institutes of Health Research (CIHR) to help bring closer to market a new anti-inflammatory drug that could ease the suffering of people with arthritis, inflammatory bowel disease and cystic fibrosis, as well as reduce damage caused by heart attacks and strokes.
|
|
May 16 2007
How can Canada survive in a globally-driven pharmaceutical market? Canada is a big, big country in size. Its neighbour, the USA, is 5% smaller and yet holds 10 times the population. Eighty percent of Canadians live within 200 km of the USA border, which perhaps says a lot about the attitude of Canadian economic dependence that exists.
|
|
May 16 2007
Perspective Commercialization of genomics over the past 10 years One of the great expectations of genomics in the 1990s was that it would radically and directly improve the business of drug discovery.
|
|
May 11 2007
BioNova heads up Atlantic Canada delegation to BIO 2007 Over 40 people representing Nova Scotia's life sciences industry were in Boston last week to take part in the world's largest biotechnology conference and showcase. The BIO convention, which draws over 20,000 delegates and almost 1,800 exhibitors, was another huge success as BioNova headed up the Atlantic Canada delegation.
|
|
April 25 2007
Warnex reviewing strategic options to enhance shareholder value Warnex Inc. has initiated a review of various strategic options for its ongoing laboratory services business in order to enhance shareholder value. These options include, but are not limited to, partnerships, mergers or the sale of the company.
|
|
April 23 2007
Agilent receives Growth Strategy Leadership award Agilent Technologies is awarded the 2006 Frost & Sullivan Growth Strategy Leadership award for the European Gene Expression market.
|
|
April 18 2007
Timing Your Freedom to Operate Analysis to Maximize Your Benefits By France Côté and Marie-Éve Bérubé-Côté
A patent provides its owner with the right to exclude others from commercializing a product covered, in part or in whole, by the patent. |
|
March 23 2007
First shelf stable juice to contain Omega-3 from fish oil hits the market Ocean Nutrition Canada Limited (ONC), supplier of MEG-3 brand Omega-3 EPA/DHA food and dietary supplement ingredients, announces that A. Lassonde Inc. has launched the first shelf stable juice containing MEG-3 healthy food ingredient throughout Canada. Not only is this the first shelf stable juice to contain MEG-3, but it is also the first shelf stable juice to contain Omega-3 from fish oil.
|
|
February 23 2007
Shoppers Drug Mart launches Halifax drug company to national status Origin BioMed Inc., a manufacturer of over-the-counter topical drug products, launches its lead product Neuragen, into one of Canada's most successful drug store chain, Shoppers Drug Mart. Neuragen is a topical oil for rapid relief of diabetic and post-shingles pain, targeting the $4 billion neuropathic pain market.
|
|
February 22 2007
Neptune Technologies & Bioressources Inc. appoints VP Business Neptune Technologies and Bioressources announces that Thierry Houillon, recently appointed member of Neptune's Board of Directors and previous CEO of Danone Canada, has joined Neptune as the vice president, Business Development, Functional Food. The appointment of Houillon will complete Neptune's executive force as the Company prepares for the upcoming penetration of the functional food market foreseen short term.
|
|
February 12 2007
BioGasoline coming soon Global Clean Energy Corp is concerned about the current and future state of the global environment. It is excited that BioDiesel is being created and used worldwide. Now for the next phase, BioGasoline. Gasoline (Petrol) usage is even greater worldwide and its new product will lower the dependence on fossil fuels, the dependence on the Middle East and help farmers worldwide.
|
|
February 12 2007
Nuvo's communications are ongoing with FDA Nuvo Research Inc. provides an update on discussions with the U.S. Food and Drug Administration regarding the approvable letter issued by the FDA for Pennsaid, a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of osteoarthritis.
|
|
February 01 2007
Bioniche receives approval to distribute E.coli vaccine The Canadian Food Inspection Agency (CFIA) has granted Bioniche Life Sciences Inc. authorization to distribute its E. coli O157:H7 cattle vaccine to Canadian veterinarians under a Permit to Release Veterinary Biologics.
|
|
February 01 2007
Squire to market Nuvo's Pennsaid Plus Squire Pharmaceuticals Inc., a subsidiary of Paladin Labs Inc. will market and sell PennsaidR Plus in Canada following a licensing agreement with Nuvo Research Inc.
|
|
January 10 2007
NRC gives start-ups a 'functional' step up To help western Canadian nutraceutical, functional food and natural health companies survive their early years, the National Research Council of Canada (NRC) has opened a BioAccess Commercialization Centre in Saskatoon, SK.
|
|
January 10 2007
Former Olympic skier to pitch Advitech drug Former Canadian Olympian Pierre Harvey will serve as the face for Quebec City, QC.-based Advitech Inc.'s psoriasis remedy DermylexTM.
|
|
January 09 2007
ART announces extension of current eXplore Optix distribution agreement with GE Healthcare Advanced Research Technologies Inc (ART), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announces the extension of its current agreement with GE Healthcare for the exclusive worldwide distribution of its eXplore Optix preclinical optical molecular imaging system.
|
|
December 18 2006
Warnex explores strategic alternatives for its pathogen detection business Warnex Inc. announces that it has decided to explore strategic alternatives for its pathogen detection business including partnerships, joint ventures or the sale of this business, in order to enhance shareholder value. The Company has mandated a U.S.-based investment banking firm, Kirchner & Company, Inc., to act as its agent in this
process. |
|
November 27 2006
Oridis Biomed Signs License Agreement Oridis Biomed has signed a license agreement with the National Institutes of Health (NIH) for the worldwide commercial use of NIH's proprietary Tissue Micro-Array (TMA) technology.
|
|
November 27 2006
NRC launches BioAccess commercialization centre The National Research Council of Canada (NRC) officially opened a new BioAccess Commercialization Centre in Saskatoon this morning. The Centre was created by NRC to assist innovative firms in Western Canadas nutraceutical, functional food and natural health products industries bring products to market and stake a claim in the lucrative $150 billion global market.
|
|
November 07 2006
Agence de la sante et des services sociaux contracts MediSolution Ltd. The Agence de la sante et des services sociaux de la Mauricie et du Centre-du-Quebec has contracted MediSolution Ltd.
|
|
September 19 2006
Monsanto Canada Launches New Soybean Line Monsanto Canada Inc. has launched the Vistive soybean, part of the company's Dekalb® brand.
|
|
September 11 2006
Regulatory Approval Sought for Cancer Wex Pharmaceuticals Inc. has requested a meeting with regulatory authorities to pursue the development of tetrodotoxin (TTX).
|
|
August 10 2006
Health Canada Green-Lights Rheumatoid Arthritis Drug Health Canada has approved Mississauga, Ont.-based Hoffmann-La Roche Ltd.s Rituxan® (rituximab) in combination with methotrexate.
|
|
August 09 2006
HIV Test Receives European Approval BioLytical Laboratories Inc. has received European approval for a rapid HIV antibody test.
|
|
July 05 2006
Cholesterol-Lowering Cheese Sold In U.K. U.K. retailer ASDA, a subsidiary of Wal-Mart, has introduced Heartfelt Plus Natural Cheese, a cheddar that contains Forbes Medi-Tech Inc.'s (Vancouver, BC) cholesterol-lowering ingredient Reducol.
|
|
June 12 2006
CellCept Receives Orphan Drug Designation The U.S. Food and Drug Administration has granted Aspreva Pharmaceuticals Corp. (Victoria, BC) and F. Hoffman-La Roche Ltd. (Basel, Switzerland) orphan drug designation for CellCept® in the treatment of pemphigus vulgaris, an autoimmune disease that causes painful skin blistering.
|
|
March 20 2006
Prostate Cancer Implant Approved Health Canada has approved Paladin Labs Inc.'s (Montreal, QC) once-yearly luteinizing hormone-releasing hormone (LHRH) implant Vantas®, used for palliative treatment of advanced prostate cancer.
|
|
March 02 2006
Amorfix Obtains Worldwide Protein Licence Drug therapy and diagnostics company Amorfix Life Sciences Ltd. (Toronto, ON) has obtained worldwide licence to superoxide dismutase-1 (SOD1), a protein known to misfold and aggregate in patients with amyotrophic lateral sclerosis (ALS), otherwise known as Lou Gehrig's disease.
|
|
February 06 2006
SoySuperb to be Launched in U.S. Winnipeg-based Brett-Young Seeds has announced the spring 2006 introduction of its SoySuperb soybean growth promoter into the U.S. market.
|
|
January 01 2006
Laser Treatment Approved in Canada Ondine Biopharma Corp.'s (Vancouver, BC) photoactivated disinfection system, Periowave, has been approved by Health Canada.
|
|
January 01 2006
FDA Approves Adherexs Chemotherapy-enhancing Drug Adherex Technologies Inc.'s (Ottawa, ON) Investigational New Drug (IND) application for eniluracil has been approved by the U.S. Food and Drug Administration.
|
|
July 29 2005
Twinstrand Gains FDA Approval of IND The U.S. Food and Drug Administration (FDA) has granted Burnaby, B.C.-based Twinstrand Therapeutics Inc. approval for its Investigational New Drug application for clinical development of TST10088.
|
|
June 14 2005
Post-marketing Observational Studies by John Sampalis, PhD Providing insight into real-life clinical practice regarding safety, efficacy and patients drug compliance.
|
|
May 30 2005
Magistral Biotech's Libracol® Approved by Health Canada Montreal, Que.-based Magistral Biotech Inc. has been granted a Natural Product Number (NPN) from Health Canada for its cholesterol-reducing product Libracol®.
|
|
May 10 2005
Market Access Planning for Emerging Medical Technology: Health Technology Assessments By Jacqueline Csonka-Peeren Medical device manufacturers looking to commercialize emerging medical technology need to consider not only strategies for intellectual property protection and regulatory approval, but also for technology diffusion, or market access. Planning for market access can help accelerate sales growth, economies of scale and brand recognition.
|
|
May 10 2005
The VC Vista Compiled by Deborah Komlos Industry Views on Canadian Biotech Financings for 2005-06
|
|
April 12 2005
Bextra Withdrawn From North American Market Pfizer Inc. (New York, NY), makers of the recently maligned arthritis drug Bextra®, has agreed to pull the product off the market in Canada and the United States.
|
|
February 08 2005
Fork in the Road By Amber Lepage-Monette Navigating the various routes to commercialization can be tricky, when companies are faced with a multitude of approaches that may very well differ from year to year and product to product.
|
|
January 17 2005
Labopharm Receives French Approval for Pain Medication Laval, Que.-based Labopharm Inc. has received French regulatory approval for its once-daily formulation of tramadol, used to treat moderate and severe pain.
|
|
September 20 2004
ID Biomedical Supplies Government With Vaccine The Government of Canada has selected ID Biomedical Corp. (Vancouver, BC) as its supplier of meningitis C vaccine for the next two years.
|
|
September 20 2004
The IPO window: who will follow MethylGene? By Patricia Nicholson The fourth quarter of 2003 and the first half of 2004 saw a surge in biotech IPOs in the United States, and led to speculation that the Canadian IPO window might be opening for the first time in several years. The biotech industry turned its eyes to MethylGene Inc. (Montreal, QC), which completed a much-anticipated initial public offering in June.
|
|
August 16 2004
New Diabetes Drug to Hit Market As of next month, a new diabetes drug hits pharmacy shelves in Mexico.
|
|
June 16 2004
The Virtues of Devices By Patricia Nicholson RIMON THERAPEUTICS PRESIDENT AND CEO MICHAEL MAY, PHD DEVELOPS THERAPEUTIC POLYMERS
|
|
January 12 2004
Early Phase Forecast By Amber Lepage-Monette Overcoming some of biotech's Biggest Hurdles
|
|
January 12 2004
Funding Canadian Medical Advances By Patricia Nicholson Individual Canadians may not think of themselves as biotech venture capitalists, but each of us has the opportunity to help commercialize scientific research - a few thousand dollars at a time.
|
